Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies in areas of high unmet medical need with an initial therapeutic focus in pulmonary arterial hypertension.
Altavant’s lead candidate is rodatristat ethyl*, a tryptophan hydroxylase (TPH) inhibitor. TPH inhibitors reduce the body’s peripheral production of serotonin, lowering circulating serotonin levels in diseases characterized by excessive production of the neurotransmitter, including pulmonary arterial hypertension (PAH), certain types of cancer, GI disorders, fibrosis and inflammation. Rodatristat ethyl is currently preparing for Phase 2 clinical development for pulmonary arterial hypertension with a number of additional indications being explored.
The Altavant team is passionate about building a culture that celebrates new ideas and persistence, with a deep commitment to pursue scientific innovation and novel approaches to drug development. We believe that in doing so, we can most effectively impact patients’ lives.
*name applied for; application pending